Across TCGA pan-cancer cohorts, ZNF385D-AS2 RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated ZNF385D-AS2 data layer.
The strongest signal is observed in uterine carcinosarcoma (UCS), where higher ZNF385D-AS2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF385D-AS2 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.
UCS, KICH, and COAD are the cancer types where ZNF385D-AS2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.